Durable Responses of Botensilimab/Balstilimab Combination in Nine Different Treatment-Resistant Cancers announced November 23, 2022
COM701 (anti-PVRIG) in Combination with Nivolumab Demonstrates Preliminary Anti-Tumor Activity and Potent Immune Activation in Metastatic MSS-CRC Patients November 16, 2022
Zentalis Pharmaceuticals Announces First ZN-c3 Clinical Development Collaboration with Pfizer November 2, 2022
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pfizer to Evaluate ERAS-007 and Palbociclib Combination October 26, 2022
First Patient Enrolled in DeFianCe Study of DKN-01 for the Treatment of Colorectal Cancer Patients October 26, 2022
Development of CYAD-101, Allogeneic TIM-based, NKG2D CAR T Candidate for Metastatic Colorectal Cancer (mCRC), to be discontinued October 19, 2022
First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Ph 1/2/3 Clinical Study for Natrunix™ Therapy for Colorectal Cancer October 19, 2022
Part 3 of the CORIST Ph 2 trial of SCO-101 as a combination treatment in patients with metastatic colorectal cancer (mCRC) initiated October 12, 2022
Randomized Ph 2 trial of onvansertib + SoC FOLFIRI/bevacizumab announced in 2L RAS-mutated mCRC September 28, 2022
TUKYSA® (tucatinib) + Trastuzumab combo Granted Priority Review by FDA for Previously Treated HER2+ve Metastatic CRC September 28, 2022
Lumakras® (Sotorasib) + Vectibix® (Panitumumab) Shows Confirmed 30% ORR In Patients With KRAS G12C-Mutated mCRC September 13, 2022
Adagrasib +/- cetuximab demonstrates promising clinical efficacy and favorable tolerability in heavily pretreated CRC patients with KRASG12C mutation September 13, 2022
Trifluridine/tipiracil + bevacizumab showed a statistically significant OS improvement vs trifluridine/tipiracil alone in Ph 3 trial in mCRC patients September 13, 2022
